Display options
Share it on

PLoS One. 2019 May 28;14(5):e0217560. doi: 10.1371/journal.pone.0217560. eCollection 2019.

Molecular detection of human T-lymphotropic virus type 1 infection among oncology patients in Germany: A retrospective view.

PloS one

Matias Ruggieri, Carolina Berini, Nicolas Ducasa, Miroslav Malkovsky, Paul Fisch, Mirna Biglione

Affiliations

  1. Institut für Klinische Pathologie, Universitätsklinikum Freiburg, Freiburg, Germany.
  2. Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), CONICET-Universidad de Buenos Aires, Buenos Aires, Argentina.
  3. UW School of Medicine and Public Health, Madison, Wisconsin, United States of America.

PMID: 31136642 PMCID: PMC6538170 DOI: 10.1371/journal.pone.0217560

Abstract

Human T-cell lymphotropic virus (HTLV) belongs to a larger group of primate T-cell lymphotropic viruses (PTLVs) within the family Retroviridae. It is estimated that 10 to 20 million people worldwide may be infected with HTLV-1. Although most of them are asymptomatic, around 5% of infected individuals may develop either HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) or Adult T-cell Leukaemia/Lymphoma (ATLL). Public Health authorities in many countries have implemented routine blood-donor tests for HTLV-specific antibodies; but this is not the case for Germany since the reported prevalence is very low (7/100,000). With the aim to evaluate retrospectively the presence of HTLV-1 among oncology patients in this country, samples stored at the Universitätsklinikum Freiburg, were analyzed. For this purpose, two different nested-PCR (n-PCR) protocols have been modified and set up for HTLV-1 detection. One positive case was detected by n-PCR among 406 samples (0,25%) in a period of 5 years (2008-2012) corresponding to a T-Cell Lymphoma. Despite the low prevalence, this virus is circulating in Germany, probably due to the increasing numbers of immigrants in these last years. Physicians should consider HTLV-1 infection and suspect it taking in account the ethnic and relation to endemic regions regardless the patient's residence.

Conflict of interest statement

The authors have declared that no competing interests exist.

References

  1. Virol J. 2017 Jan 30;14(1):14 - PubMed
  2. Clin Microbiol Rev. 2010 Jul;23(3):577-89 - PubMed
  3. Transfus Med Rev. 2004 Jan;18(1):46-57 - PubMed
  4. Front Microbiol. 2012 Nov 15;3:388 - PubMed
  5. AIDS Res Hum Retroviruses. 1998 Sep 1;14(13):1199-203 - PubMed
  6. Clin Infect Dis. 2013 Nov;57(10):1417-24 - PubMed
  7. J Clin Microbiol. 1992 Jun;30(6):1605-7 - PubMed
  8. Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 - PubMed
  9. J Infect Dis. 1992 Feb;165(2):369-72 - PubMed
  10. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S236-41 - PubMed
  11. F1000Res. 2019 Feb 28;8: - PubMed
  12. Viruses. 2015 Oct 28;7(11):5643-58 - PubMed
  13. Transplantation. 2003 Jan 15;75(1):102-4 - PubMed
  14. Virology. 1994 Jul;202(1):212-23 - PubMed
  15. Clin Lab. 2017 Feb 1;63(2):227-233 - PubMed
  16. J Clin Microbiol. 1995 Jul;33(7):1735-8 - PubMed
  17. BMC Public Health. 2016 Aug 15;16:787 - PubMed
  18. Clin Microbiol Rev. 2000 Oct;13(4):559-70 - PubMed
  19. Clin Diagn Virol. 1996 Nov;7(2):85-92 - PubMed
  20. PLoS One. 2017 Aug 22;12(8):e0183496 - PubMed
  21. Oncogene. 2005 Sep 5;24(39):6058-68 - PubMed
  22. AIDS Res Hum Retroviruses. 2005 Jan;21(1):1-4 - PubMed
  23. PLoS Negl Trop Dis. 2018 Mar 12;12(3):e0006281 - PubMed
  24. AIDS Res Hum Retroviruses. 1999 May 20;15(8):699-705 - PubMed
  25. Clin Investig. 1992 Nov;70(11):1013-8 - PubMed
  26. J Virol Methods. 1992 Nov;40(2):163-73 - PubMed

MeSH terms

Publication Types